Results 131 to 140 of about 6,192 (194)

Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors. [PDF]

Eur J Med Res
Saber K, Ismail R, Bassyouni A, El-Shafee M, Hassan MH.   +4 more
europepmc   +1 more source

Development and Validation of High-Performance Thin Layer Chromatographic Method for the Simultaneous Estimation of Dapagliflozin and Vildagliptin in Fixed-Dose Combination. [PDF]

Turk J Pharm Sci
Krishnamoorthy YV, Azhlwar S, Krishnamoorthy V.   +2 more
europepmc   +1 more source

<i>Candida glabrata</i> Prostatitis: A Rare Case in a Patient With Type 2 Diabetes Mellitus on Dapagliflozin Treatment. [PDF]

Case Rep Infect Dis
Torres García EG, Marcelo Calvo C, Navarro-Carrera P, Díez-Vidal A, Díaz-Pollán B.   +4 more
europepmc   +1 more source

Therapeutic impact of vildagliptin vs. gliclazide on insulin resistance and advanced glycated end product levels in newly diagnosed Egyptian diabetics: a randomized controlled trial. [PDF]

Eur J Clin Pharmacol
Elemary T, Abdelrahim MEA, Nicola M, Zaafar D.   +3 more
europepmc   +1 more source

Antidiabetes agents and risk of incident depression in 686,522 people with type 2 diabetes mellitus: A 20-year population-based cohort study. [PDF]

Psychol Med
Ho MTH, Chan JKN, Lo HKY, Fang CZ, Wong CSM, Lee KCK, Lai FTT, Ng APP, Wong WCW, Chang WC.   +9 more
europepmc   +1 more source

Vildagliptin modulates the microbiota and induces an immunometabolic profile compatible with neuroprotection in type 2 diabetes. [PDF]

Sci Rep
de Macedo JCC, Guadagnini D, Assalin HB, Oliveira ES, Magro DO, Alborghetti MR, Sforça ML, Rocco SA, Santos A, Saad MJA.   +9 more
europepmc   +1 more source

<i>In Vivo</i> and <i>In Silico</i> Analysis of Quercetin's Effects on Glycemic Regulation. [PDF]

Scientifica (Cairo)
Jumriani J, Aswad M, Ratnawati R, Filmaharani F, Nurhidayah A, Azmin MR, Roosevelt A, Alfiana R, Hardiyanti W, Latada NP, Mudjahid M, Nainu F.   +11 more
europepmc   +1 more source

The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy. [PDF]

Front Endocrinol (Lausanne)
Kong D, Shen Z, Jiang L, Xie X, Yan R, Jing T, Hu Y, Ma J.   +7 more
europepmc   +1 more source

Unravelling the mechanism by which vildagliptin and linagliptin inhibit pyroptosis in lung injury through the NLRP3 inflammatory pathway in type 1 diabetic rats. [PDF]

Sci Rep
Sedik AA, El-Nasr NMEA, Khalil WKB, El-Mosallamy AEMK.   +3 more
europepmc   +1 more source

Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes. [PDF]

Cureus
Khanna S, Malik M, Ahmad R.
europepmc   +1 more source